Antiglucocorticoids in psychiatry

Advances in Psychiatric Treatment

Volumn 15, Issue 4, 2009, Pages 242-249

  McIsaac, Sean A ^a   Westrin, Åsa ^b   Young, Allan H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIFEPRISTONE; PRASTERONE; SEROTONIN;

DEPRESSION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; POSTTRAUMATIC STRESS DISORDER; REVIEW; SUICIDE;

EID: 77949537643     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.105.001834     Document Type: Review

References (64)

1. Arana GW, Santos AB, Laraia MT. et al (1995) Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. American Journal of Psychiatry; 152: 265-7.
2. Arato M, Banki CM, Bissette G, et al (1989) Elevated CSF CRF in suicide victims. Biological Psychiatry; 25: 355-9.
3. Belanoff JK, Rothschild AJ, Cassidy F, et al (2002) An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry; 52: 386-92.
4. Board F, Wadeson R, Persky H (1957) Depressive affect and endocrine functions: blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. Archives of Neurology and Psychiatry; 78: 612-20.
5. Broadbear JH, Winger G, Rivier JE, et al (2004) Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology; 29: 1112-21.
6. Cardounel A, Regelson W, Kalimi M (1999) Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proceedings of the Society for Experimental Biology and Medicine; 222: 145-9
7. Cavanagh JTO, Van Beck M, Muir W, et al (2002) Case-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. British Journal of Psychiatry; 180: 320-6.
8. Coryell W, Young E, Carroll B (2006) Hyperactivity of the hypothalamic-pituitary - adrenal axis and mortality in major depressive disorder Psychiatry Research; 142: 99-104.
9. Cowen PJ (2002) Cortisol, serotonin and depression: all stressed out? British Journal of Psychiatry; 180: 99-100.
10. DeBattista C, Belanoff J (2005) C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease. Current Alzheimer Research; 2: 125-9.
11. Delva NJ, Matthews DR. Cowen PJ (1996) Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs. Biological Psychiatry; 39: 100-6
12. Dinan TG, (1996) Sorotonin and the regulation of hypothalamic - pituitary - adrenal axis function. Life Sciences; 58: 1683-94
13. Dinan TG, Scott LV (2005) Anatomy of melancholia: focus on hypothalamic - pituitary - adrenal axis overactivity and the role of vasopressin. Journal of Anatomy; 207: 259-64
14. Dorovini-Zis K, Zis AP (1987) Increased adrenal weight in victims of violent suicide. American Journal of Psychiatry; 144: 1214-5.
15. French JA, Fite JE, Jensen H, et al (2007) Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). American Journal of Primatology; 69: 877-9.
16. Gallagher P, Watson S, Smith MS, et al (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biological Psychiatry; 57: 155-61.
17. Gallagher P, Malik N, Newham J, et al (2008) Antiglucocorticoid treatments for mood disorders. Cochrane Database of Systematic Reviews; issue 1: CD005168.
18. Gartside SE, Leitch MM, Young AH (2003) Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. Neuropsychopharmacology; 28: 1572-8.
19. Glezer, I, Rivest, S (2004) Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist; 10: 538-52.
20. Goldstein ET, Preskorn SH (1989) Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder. American Journal of Psychiatry; 146: 1076-7.
21. Harmer CJ, Bhagwagar Z, Shelley N, et al (2003) Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology; 167: 112-4.
22. Huffman JC, Stern TA (2007) Neuropsychiatric consequences of cardiovascular medications. Dialogues in Clinical Neurosciences; 9: 29-45.
23. Hunt PJ, Gurnell EM, Huppert FA, et al (2000) Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology and Metabolism; 85: 4850-6
24. Jahn H, Schick M, Kiefer F, et al (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Archives of General Psychiatry; 61: 1235-44.
25. Karssen AM, Meijer OC, Berry A, et al (2005) Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology; 146: 5587-95
26. Kunugi H, Ida I, Owashi T, et al (2006) Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic - pituitary - adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study Neuropsychopharmacology; 31: 212-20.
27. Lester D (1992) The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry; 25: 265-70.
28. Lewis LD, Cochrane GM (1983) Psychosis in a child inhaling budesonide. Lancet; 2(8350): 634.
29. Lopez JF, Palkovits M, Arato M, et al (1992) Localization and quantification of pro-opiomelanocortin mRNA and glucocorticoid receptor mRNA in pituitaries of suicide victims. Neuroendocrinology; 56: 491-501.
30. Lupien SJ, McEwen BS (1997) The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Research Reviews; 24: 1-27.
31. Man MS, Young AH, McAllister-Williams RH (2002) Corticosterone modulation of somatodendritic 5-HT1A receptor function in mice. Journal of Psychopharmacology; 16: 245-52.
32. McQuade R, Young AH (2000) Future therapeutic targets in mood disorders: the glucocorticoid receptor. British Journal of Psychiatry; 177: 390-5.
33. Mendelson SD, McEwen BS (1992) Quantitative autoradiographic analyses of the time course and reversibility of corticosterone-induced decreases in binding at 5-HT1A receptors in rat forebrain. Neuroendocrinology; 56: 881-8.
34. Meyboom RH, de Graaf-Breederveld N (1988) Budesonide and psychic side effects. Annals of Internal Medicine; 109: 683.
35. Murphy BE, Filipini D, Ghadirian AM (1993) Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. Journal of Psychiatry and Neuroscience; 18: 209-13.
36. Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology; 22 (suppl 1): s125-32.
37. Nelson JC, Davis JM (1997) DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry; 154: 1497-503.
38. Nemeroff CB, Owens MJ, Bissette G, et al (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Archives of General Psychiatry; 45: 577-9
39. Ormiston T, Wolkowitz OM, Reus VI, et al (2004) Hormonal changes with cholesterol reduction: a double-blind pilot study. Journal of Clinical Pharmacy and Therapeutics; 29: 71-3.
40. Pfennig A, Kunzel HE, Kern N, et al (2005) Hypothalamus - pituitary - adrenal system regulation and suicidal behavior in depression. Biological Psychiatry; 57: 336-42.
41. Phelan MC (1989) Beclomethasone mania. British Journal of Psychiatry; 155: 871-2.
42. Porter RJ, Gallagher P, Watson S, et al (2004) Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacology; 173: 1-17.
43. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, et al (1995) Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. American Journal of Psychiatry; 152: 1372-6.
44. Ravaris CL, Sateia MJ, Baroza KW, et al (1986) Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Archives of General Psychiatry; 45: 966-7.
45. Sapolsky RM, Krey LC, McEwen BS (1986) The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocrine Reviews; 7: 284-301
46. Thompson JM, Gallagher P, Hughes JH, et al (2005) Neurocognitive impairment in euthymic patients with bipolar affective disorder. British Journal of Psychiatry; 186: 32-40.
47. Walder DJ, Walker EF, Lewine RJ (2000) Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biological Psychiatry; 48: 1121-32
48. Watson S, Gallagher P, Ritchie JC, et al (2004) Hypothalamic - pituitary - adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry; 184: 496-502.
49. Watson S, Gallagher P, Ferrier IN, et al (2006) Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. Journal of Psychiatric Reseach; 40: 353-9.
50. Webster MJ, Knable MB, O'Grady J, et al (2002) Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry; 7: 985-84.
51. Westrin A, Nimeus A (2003) The dexamethasone suppression test and CSF-5-HIAA in relation to suicidality and depression in suicide attempters. European Psychiatry; 18: 166-71.
52. Wolkowitz OM, Reus VI, Weingartner H, et al (1990) Cognitive effects of corticosteroids. American Journal of Psychiatry; 147: 1297-303.
53. Wolkowitz OM, Reus VI, Keebler A, et al (1999) Double-blind treatment of major depression with dehydroepiandrosterone. American Journal of Psychiatry; 156: 646-9
54. Yehuda, R (2001) Biology of posttraumatic stress disorder. Journal of Clinical Psychiatry; 62 (suppl 17): 41-6
55. Yehuda R (2006) Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Annals of the New York Academy of Sciences; 1071: 137-66.
56. Young AH (1994a) Glucocorticoids, serotonin and mood. British Journal of Psychiatry; 165: 271-2.
57. Young AH, Sharpley AL, Campling GM, et al (1994b) Effects of hydrocortisone on brain 5-HT function and sleep. Journal of Affective Disorders; 32: 139-46.
58. Young AH, Sahakian BJ, Robbins TW, et al (1999) The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology; 145: 260-66.
59. Young AH, Gallagher P, Porter RJ (2002) Elevation of the cortisol - dehydroepiandrosterone ratio in drug-free depressed patients. American Journal of Psychiatry; 159: 1237-9
60. Young AH, Gallagher P, Watson S, et al (2004) Improvements in neurocognitiva function and mood following adjunctive treatment with mifapristone (RU 466) in bipolar disorder. Neuropsychopharmacology; 29: 1538-45.
61. Young EA, Breslau N (2004a) Saliva curtisol in posttraumatic stress disorder a community epidemiologic study. Biological Psychiatry; 56: 205-8.
62. Young EA, Altemus M, Lopez JF, et al (2004b) HPA axis activation in major depression and response to fluoxatine: a pilot study. Psychoneuroendocrinology; 29: 1190-204.
63. Zhou, DF, Shan, YC, Shu, LN, et al (1967) Dexamathasona suppression test and urinary MHPG X S04 determination in depressive disorders. Biological psychiatry; 22: 683-91.
64. Zobel AW, Nickel T, Sonntag A, et al (2001) Cortisol response in the combined dexamathasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Journal of Psychiatric Research; 35: 83-94.